ABSTRACT
PURPOSE: To evaluate the effectiveness of silicone oil removal from the human eye under in vitro conditions. METHODS: Six keratoplasty donor eyes were vitrectomized and filled with silicone oil (5000 centistokes). After oil removal, the amount of residual oil was determined by quantifying the silicon content of the eyes. Six control eyes were prepared without oil filling. RESULTS: The six control specimens showed a silicon content of 2.83-10.2 microg (mean 5.06 microg, SD 3.19), the six test specimens a silicon content of 70.54-297.10 microg (mean 163.91 microg, SD 86.89). The difference is significant (p<0.05). The amount of residual oil in the test eyes was 192.0-856.2 microg (0.0037-0.0179% of the applicated oil quantity). CONCLUSION: The low magnitude of residual intraocular oil after oil removal shows that silicone oil could be removed to almost 100% when emulsification and biological mechanisms of oil retention are excluded. This could favour early silicone oil removal.
Subject(s)
Drainage/standards , Eye/metabolism , Oils/metabolism , Postoperative Care , Silicones/metabolism , Vitrectomy , Cadaver , Corneal Transplantation , Humans , Postoperative PeriodABSTRACT
For many analyses of the vitreous, it is essential to obtain undiluted vitreous specimens under sterile conditions intraoperatively. In this new technique, a metal device is integrated into the aspiration system. The device fits on standard laboratory plastic containers with integrated caps. Undiluted vitreous accumulates in the container, which is then removed and sent to the laboratory. With a new container in place, vitrectomy can be continued as usual. This technique is simple, safe, effective, and inexpensive.
Subject(s)
Biopsy/instrumentation , Vitrectomy , Vitreous Body/pathology , Biopsy/methods , Humans , Intraoperative PeriodABSTRACT
Both diagnostic and therapeutic problems remain in the treatment of basal cell carcinomas of the eyelid. Incorrect initial diagnosis and resulting inadequate treatment can lead to the loss of the bulbus. Inadequate follow up may result in failure to detect a recurrent tumor. We retrospectively studied 226 patients with basal cell carcinoma of the eyelid who had surgery some time between 1980 and 1989. In 179 patients, a primary lid tumor was removed; the recurrence rate for these patients was 6.1%. Forty-seven patients had surgery for secondary eyelid basaliomas; the recurrence rate for these patients was 14.8%. These recurrence rates correlated clearly with the horizontal extent and depth of the tumor, and with the appearance of the sclerodermiform type. The fact that recurrences were found after 3 years demonstrates the importance of long-term follow up in these patients, especially in those with secondary tumors and tumors of exceptional height.
Subject(s)
Carcinoma, Basal Cell/surgery , Eyelid Neoplasms/surgery , Postoperative Care , Adult , Aged , Aged, 80 and over , Female , Follow-Up Studies , Humans , Longitudinal Studies , Male , Middle Aged , Neoplasm Recurrence, Local , Retrospective StudiesABSTRACT
In the treatment of basal cell carcinoma there are still diagnostic and therapeutic problems. The wrong diagnosis resulting in inadequate treatment can lead to loss of the bulbus. In the following study 226 patients were operated on for basal cell carcinoma between 1980 and 1990. In 179 patients a primary eyelid tumor was removed and the rate of recurrence was 5.0%. In 47 patients with secondary eyelid tumors (recurrent tumors) a recurrence rate of 14.8% was found. The examination methods, surgical treatment and results are presented.
